Matching articles for "apixaban"

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • January 8, 2024;  (Issue 1693)
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 | Show Full IntroductionHide Full Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • July 25, 2022;  (Issue 1655)
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • July 25, 2022;  (Issue 1655)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 | Show Full IntroductionHide Full Introduction

Drugs for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • September 9, 2019;  (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently...
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Med Lett Drugs Ther. 2019 Sep 9;61(1580):137-44 | Show Full IntroductionHide Full Introduction

Andexxa - An Antidote for Apixaban and Rivaroxaban

   
The Medical Letter on Drugs and Therapeutics • June 18, 2018;  (Issue 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor...
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto). Andexanet alfa is the second antidote for a direct oral anticoagulant to become available in the US, and the fi rst for factor Xa inhibitors. Idarucizumab (Praxbind) was approved in 2015 for reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Andexanet alfa has not been approved to date for reversal of anticoagulation with the direct factor Xa inhibitors edoxaban (Savaysa) or betrixaban (Bevyxxa).
Med Lett Drugs Ther. 2018 Jun 18;60(1549):99-101 | Show Full IntroductionHide Full Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • March 12, 2018;  (Issue 1542)
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US guidelines for treatment of VTE were published in 2016.
Med Lett Drugs Ther. 2018 Mar 12;60(1542):41-8 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • March 12, 2018;  (Issue 1542)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2018 Mar 12;60(1542):e51-4 | Show Full IntroductionHide Full Introduction

Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness

   
The Medical Letter on Drugs and Therapeutics • January 1, 2018;  (Issue 1537)
The FDA has approved betrixaban (Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who...
The FDA has approved betrixaban (Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have moderately or severely restricted mobility and other risk factors for VTE. Betrixaban is the first oral anticoagulant to be approved in the US for this indication.
Med Lett Drugs Ther. 2018 Jan 1;60(1537):4-5 | Show Full IntroductionHide Full Introduction

Prescription Drug Prices in the US

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017;  (Issue 1521)
Per capita spending on prescription drugs in the US is higher than in other industrialized nations,...
Per capita spending on prescription drugs in the US is higher than in other industrialized nations, including Canada.
Med Lett Drugs Ther. 2017 May 22;59(1521):81-3 | Show Full IntroductionHide Full Introduction

Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • February 27, 2017;  (Issue 1515)
With the widespread adoption of the CHA2DS2-VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial...
With the widespread adoption of the CHA2DS2-VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial fibrillation has, however, been associated with an increased risk of falls, and older patients starting warfarin for atrial fibrillation have a high rate of hospitalization for intracranial bleeding. Many practitioners are reluctant, therefore, to prescribe an oral anticoagulant for elderly patients who are at high risk for falls.
Med Lett Drugs Ther. 2017 Feb 27;59(1515):35-6 | Show Full IntroductionHide Full Introduction

Which Oral Anticoagulant for Atrial Fibrillation?

   
The Medical Letter on Drugs and Therapeutics • April 11, 2016;  (Issue 1492)
Direct-to-consumer advertisements continue to urge patients who take warfarin (Coumadin, and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral...
Direct-to-consumer advertisements continue to urge patients who take warfarin (Coumadin, and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral anticoagulants.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):45-6 | Show Full IntroductionHide Full Introduction

Idarucizumab (Praxbind) - An Antidote for Dabigatran

   
The Medical Letter on Drugs and Therapeutics • November 23, 2015;  (Issue 1482)
The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Idarucizumab is...
The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Idarucizumab is the first specific reversal agent to become available for one of the new oral anticoagulants.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):157-8 | Show Full IntroductionHide Full Introduction

Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • March 30, 2015;  (Issue 1465)
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic...
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):43-5 | Show Full IntroductionHide Full Introduction

Antithrombotic Drugs

   
The Medical Letter on Drugs and Therapeutics • October 27, 2014;  (Issue 1454)
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and...
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Med Lett Drugs Ther. 2014 Oct 27;56(1454):103-8 | Show Full IntroductionHide Full Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • July 7, 2014;  (Issue 1446)
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been...
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Med Lett Drugs Ther. 2014 Jul 7;56(1446):53-8 | Show Full IntroductionHide Full Introduction

New Oral Anticoagulants for Acute Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • January 6, 2014;  (Issue 1433)
Anticoagulants are the drugs of choice for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism...
Anticoagulants are the drugs of choice for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE).
Med Lett Drugs Ther. 2014 Jan 6;56(1433):3-4 | Show Full IntroductionHide Full Introduction

Rethinking Warfarin for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • September 30, 2013;  (Issue 1426)
Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers Squibb). Apixaban...
Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers Squibb). Apixaban is the latest of 3 new oral anticoagulants now competing with warfarin (Coumadin, and others) for the oral anticoagulant market.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):77 | Show Full IntroductionHide Full Introduction

Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation

   
The Medical Letter on Drugs and Therapeutics • July 8, 2013;  (Issue 1420)
The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is...
The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is the only 4-factor PCC available in the US.
Med Lett Drugs Ther. 2013 Jul 8;55(1420):53-4 | Show Full IntroductionHide Full Introduction

Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • February 4, 2013;  (Issue 1409)
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It...
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the third new oral anticoagulant to be approved for this indication as an alternative to warfarin.
Med Lett Drugs Ther. 2013 Feb 4;55(1409):9-10 | Show Full IntroductionHide Full Introduction

Choice of an Oral Anticoagulant in Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • October 1, 2012;  (Issue 1400)
Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following:...
Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following: congestive heart failure, hypertension, age ≥75 years, diabetes, or prior stroke or transient ischemic attack (CHADS2 score ≥1).
Med Lett Drugs Ther. 2012 Oct 1;54(1400):79-80 | Show Full IntroductionHide Full Introduction

Antithrombotic Drugs

   
The Medical Letter on Drugs and Therapeutics • October 1, 2011;  (Issue 110)
Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but...
Arterial thrombi are composed mainly of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Treat Guidel Med Lett. 2011 Oct;9(110):61-6 | Show Full IntroductionHide Full Introduction